Why the Obesity Drug Revolution Is a Work in Progress

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. Yet the interest in these miracle drugs has presented some challenges. Not only are insurance companies sometimes balking at paying for the medications, which can cost as much as $16,000 a year, but ongoing shortages have created opportunities fo

Read Full Article